Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System

Chris Frei, Hannah Le, Daniel McHugh, Kellie Ryan, Xavier Jones, Samantha Galley, Kathleen Franklin, Courtney J. Baus, Juan Tavera, Michelle Janania-Martinez, David Gregorio, Snegha Ananth, Ricardo Uribe, Prathibha Surapaneni, Manuel Espinoza-Gutarra, Michael M. Song, Chengwen Teng, Obiageri O. Obodozie-Ofoegbu, Zohra Nooruddin

Research output: Contribution to journalArticlepeer-review

Abstract

The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% (n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% (n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% (n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.

Original languageEnglish (US)
Pages (from-to)1664-1673
Number of pages10
JournalLeukemia and Lymphoma
Volume62
Issue number7
DOIs
StatePublished - 2021

Keywords

  • adverse events
  • chart review
  • Chronic lymphocytic leukemia
  • discontinuation
  • dose reduction
  • novel agents

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System'. Together they form a unique fingerprint.

Cite this